ALNYLAM PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Debt Securities, Available-for-sale, Amortized Cost of $1.26 billion as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-10-30
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $1.26B.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $1.76B.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $1.64B.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.79B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-09-30 | $1.26B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $1.76B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $1.64B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $1.79B 10-Q · filed 2025-10-30 | |
| 2024-09-30 | $1.67B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $1.69B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $1.74B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $1.65B 10-K · filed 2025-02-13 | |
| 2023-09-30 | $1.39B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $1.39B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.38B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $1.42B 10-K · filed 2024-02-15 | |
| 2022-09-30 | $1.25B 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $1.60B 10-Q · filed 2022-07-28 | |
| 2022-03-31 | $1.74B 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $1.61B 10-K · filed 2023-02-23 | |
| 2021-09-30 | $1.17B 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $1.10B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $1.27B 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $1.35B 10-K · filed 2022-02-10 | |
| 2020-09-30 | $1.29B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.27B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $968.66M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $1.32B 10-K · filed 2021-02-11 | |
| 2019-09-30 | $1.47B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $1.59B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $1.05B 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $884.50M 10-K · filed 2020-02-13 | $663.22M 10-K · filed 2019-02-14 |
| 2018-09-30 | $905.82M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $1.08B 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $1.17B 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $1.06B 10-K · filed 2019-02-14 | |
| 2017-09-30 | $798.74M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $690.34M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $642.18M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $750.54M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $870.86M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $858.98M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $977.25M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $1.10B 10-K · filed 2017-02-15 | |
| 2015-09-30 | $1.19B 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.25B 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $1.14B 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $807.84M 10-K · filed 2016-02-12 | |
| 2014-09-30 | $833.06M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $875.31M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $650.58M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $297.32M 10-K · filed 2015-02-13 | |
| 2013-09-30 | $355.38M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $355.05M 10-Q · filed 2013-08-09 | |
| 2012-12-31 | $174.89M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |